Get the Stockscreener App
26.63
2.99%
-0.82
Tango Therapeutics Inc stock is traded at $26.63, with a volume of 2.46M.
It is down -2.99% in the last 24 hours and down -8.55% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$27.45
Open:
$27.5
24h Volume:
2.46M
Relative Volume:
0.61
Market Cap:
$4.34B
Revenue:
$56.99M
Net Income/Loss:
$-107.23M
P/E Ratio:
-32.48
EPS:
-0.8199
Net Cash Flow:
$-142.55M
1W Performance:
-6.76%
1M Performance:
-8.55%
6M Performance:
+127.41%
1Y Performance:
+294.52%
1-Day Range:
$26.25
$27.66
1-Week Range:
$26.25
$29.34
52-Week Range:
$5.595
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
26.63 | 4.34B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Canaccord Genuity | Buy |
| Feb-23-26 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
TradingKey - TradingKey
TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tango Therapeutics, Inc. (TNGX) stock price, news, quote and history - Yahoo Finance UK
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Yahoo Finance Singapore
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TNGX Maintained by Mizuho -- Price Target Raised to $40.00 - GuruFocus
Mizuho raises Tango Therapeutics stock price target on combo data - Investing.com
Mizuho raises Tango Therapeutics stock price target on combo data By Investing.com - Investing.com Canada
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com - Investing.com Australia
JPMorgan initiates Tango Therapeutics stock at Overweight - Investing.com UK
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues - Yahoo Finance
TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target - marketscreener.com
J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46 - Moomoo
Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
2 Monster Growth Stocks Analysts Think Can Reach New Highs - The Globe and Mail
Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Tango Therapeutics president Crystal Adam sells $798,908 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics president Crystal Adam sells $798,908 in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares - Stock Titan
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Yahoo Finance
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell Microcap Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
TNGX Upgraded by Jefferies -- Price Target Raised to $60 - GuruFocus
Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target Is $27 - Moomoo
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tango Therapeutics Inc Stock (TNGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Jul 01 '26 |
Sale |
29.59 |
27,000 |
798,908 |
115,743 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):